Advertisement
News
Advertisement

Bluebird bio names first SAB members, expanding clinical trials

Mon, 03/21/2011 - 11:38am
Mass High Tech: The Journal of New England Technology

Bluebird bio, a Cambridge gene-therapy company, appointed its first scientific advisory board (SAB) members today, and said it would expand clinical trials in its lead compounds.

The SAB comes on the heels of announcements last week of a new chief medical officer, Alexandre P. LeBeaut, a pharmaceutical industry veteran, and a deal with the French Muscular Dystrophy Association worth up to $4.2 million for its LentiGlobin treatment for beta-thalassemia and sickle cell anemia.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading